Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Retained Earnings (2016 - 2025)

Historic Retained Earnings for RedHill Biopharma (RDHL) over the last 15 years, with Q2 2025 value amounting to -$418.1 million.

  • RedHill Biopharma's Retained Earnings fell 196.61% to -$418.1 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$418.1 million, marking a year-over-year decrease of 196.61%. This contributed to the annual value of -$414.8 million for FY2024, which is 173.3% down from last year.
  • Per RedHill Biopharma's latest filing, its Retained Earnings stood at -$418.1 million for Q2 2025, which was down 196.61% from -$414.8 million recorded in Q4 2024.
  • Over the past 5 years, RedHill Biopharma's Retained Earnings peaked at -$302.3 million during Q1 2021, and registered a low of -$433.9 million during Q4 2022.
  • In the last 5 years, RedHill Biopharma's Retained Earnings had a median value of -$390.3 million in 2022 and averaged -$385.9 million.
  • In the last 5 years, RedHill Biopharma's Retained Earnings crashed by 3582.46% in 2021 and then skyrocketed by 602.15% in 2023.
  • Quarter analysis of 5 years shows RedHill Biopharma's Retained Earnings stood at -$367.9 million in 2021, then dropped by 17.94% to -$433.9 million in 2022, then rose by 6.02% to -$407.7 million in 2023, then dropped by 1.73% to -$414.8 million in 2024, then decreased by 0.8% to -$418.1 million in 2025.
  • Its Retained Earnings stands at -$418.1 million for Q2 2025, versus -$414.8 million for Q4 2024 and -$410.1 million for Q2 2024.